Xortx Therapeutics Stock Revenue
| XRTX Stock | USD 1.27 0.06 4.96% |
XORTX Therapeutics fundamentals help investors to digest information that contributes to XORTX Therapeutics' financial success or failures. It also enables traders to predict the movement of XORTX Stock. The fundamental analysis module provides a way to measure XORTX Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XORTX Therapeutics stock.
| Last Reported | Projected for Next Year |
XORTX | Revenue |
XORTX Therapeutics Company Revenue Analysis
XORTX Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Historical and Projected quarterly revenue of XORTX
Projected quarterly revenue analysis of XORTX Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of XORTX Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in XORTX Therapeutics' stock price.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, XORTX Therapeutics reported 0.0 of revenue. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
XORTX Therapeutics is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 4.46 Million. XORTX Therapeutics adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.XORTX Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of XORTX Therapeutics from analyzing XORTX Therapeutics' financial statements. These drivers represent accounts that assess XORTX Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XORTX Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 8.0M | 10.1M | 11.3M | 134.3M | 5.7M | 5.5M | |
| Enterprise Value | 7.8M | 10.1M | 11.2M | 123.9M | 2.3M | 2.2M |
XORTX Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in XORTX Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of XORTX Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing XORTX Therapeutics' value.| Shares | Royal Bank Of Canada | 2024-06-30 | 1.2 K | Advisor Group Holdings, Inc. | 2024-06-30 | 1.2 K | Hartland & Co | 2024-06-30 | 277 | Jpmorgan Chase & Co | 2024-06-30 | 254 | Bank Of Montreal | 2024-06-30 | 0.0 | Bmo Capital Markets Corp. | 2024-06-30 | 0.0 | Citadel Advisors Llc | 2024-09-30 | 0.0 |
XORTX Fundamentals
| Return On Equity | -0.29 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 2.11 M | ||||
| Shares Outstanding | 3.22 M | ||||
| Shares Owned By Insiders | 3.01 % | ||||
| Shares Owned By Institutions | 6.03 % | ||||
| Number Of Shares Shorted | 3.74 K | ||||
| Price To Earning | 170.67 X | ||||
| Price To Book | 1.92 X | ||||
| EBITDA | (6.47 M) | ||||
| Net Income | (2.16 M) | ||||
| Cash And Equivalents | 13.42 M | ||||
| Cash Per Share | 1.03 X | ||||
| Total Debt | 11.51 K | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 14.09 X | ||||
| Book Value Per Share | 2.32 X | ||||
| Cash Flow From Operations | (6.58 M) | ||||
| Short Ratio | 0.02 X | ||||
| Earnings Per Share | 0.12 X | ||||
| Price To Earnings To Growth | 9.08 X | ||||
| Target Price | 12.17 | ||||
| Beta | -0.21 | ||||
| Market Capitalization | 4.34 M | ||||
| Total Asset | 5.47 M | ||||
| Retained Earnings | (17.85 M) | ||||
| Working Capital | 3.77 M | ||||
| Current Asset | 341.74 M | ||||
| Current Liabilities | 109.37 M | ||||
| Net Asset | 5.47 M |
About XORTX Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XORTX Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XORTX Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XORTX Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for XORTX Stock Analysis
When running XORTX Therapeutics' price analysis, check to measure XORTX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XORTX Therapeutics is operating at the current time. Most of XORTX Therapeutics' value examination focuses on studying past and present price action to predict the probability of XORTX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XORTX Therapeutics' price. Additionally, you may evaluate how the addition of XORTX Therapeutics to your portfolios can decrease your overall portfolio volatility.